Engineering an aglycosylated Fc variant for enhanced FcγRI engagement and pH-dependent human FcRn binding

Sang Taek Jung, Tae Hyun Kang, Dong il Kim

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

The clinical use of therapeutic antibodies has increased sharply because of their many advantages over conventional small molecule drugs, particularly with respect to their affinity, specificity, and serum stability. Tumor or infected cells are removed by the binding of antibody Fc regions to Fc gamma receptors (FcγRs), which stimulate the activation of immune effector cells. Aglycosylated full-length IgG antibodies expressed in bacteria have different Fc conformations compared to their glycosylated counterparts produced in mammalian cells. As a result, they are unable to bind FcγRs, resulting in little to no activation of immune effector cells. In this study, we created a combinatorial library randomized at the upper CH2 loops of an aglycosylated Fc variant (Fc5: E382V/M428) and used a high-throughput flow cytometry library screening method, combined with bacterial display of homodimeric Fc domains for enhanced FcγR binding affinity. The trastuzumab Fc variant containing the identified mutations (Q295R, L328W, A330V, P331A, I332Y, E382V, M428I) not only exhibited over 120 fold higher affinity of specific binding to FcγRI than wild type aglycosylated Fc, but also retained pH-dependent FcRn binding. These results show that an aglycosylated antibody expressed in bacteria can be evolved for novel FcγR affinity and specificity.

Original languageEnglish
Pages (from-to)780-789
Number of pages10
JournalBiotechnology and Bioprocess Engineering
Volume19
Issue number5
DOIs
Publication statusPublished - 2014 Nov 20
Externally publishedYes

Fingerprint

Antibodies
IgG Receptors
Bacteria
Chemical activation
Flow cytometry
Therapeutic Uses
Conformations
Tumors
Flow Cytometry
Screening
Immunoglobulin G
Display devices
Cells
Throughput
Mutation
Molecules
Serum
Pharmaceutical Preparations
Neoplasms

Keywords

  • antibody Fc
  • directed evolution
  • effector functions
  • FcγRI (CD64)
  • neonatal Fc receptor (FcRn)

ASJC Scopus subject areas

  • Biotechnology
  • Bioengineering
  • Applied Microbiology and Biotechnology
  • Biomedical Engineering

Cite this

Engineering an aglycosylated Fc variant for enhanced FcγRI engagement and pH-dependent human FcRn binding. / Jung, Sang Taek; Kang, Tae Hyun; Kim, Dong il.

In: Biotechnology and Bioprocess Engineering, Vol. 19, No. 5, 20.11.2014, p. 780-789.

Research output: Contribution to journalArticle

@article{37c70ea93b9d46db969e6c571cf7b309,
title = "Engineering an aglycosylated Fc variant for enhanced FcγRI engagement and pH-dependent human FcRn binding",
abstract = "The clinical use of therapeutic antibodies has increased sharply because of their many advantages over conventional small molecule drugs, particularly with respect to their affinity, specificity, and serum stability. Tumor or infected cells are removed by the binding of antibody Fc regions to Fc gamma receptors (FcγRs), which stimulate the activation of immune effector cells. Aglycosylated full-length IgG antibodies expressed in bacteria have different Fc conformations compared to their glycosylated counterparts produced in mammalian cells. As a result, they are unable to bind FcγRs, resulting in little to no activation of immune effector cells. In this study, we created a combinatorial library randomized at the upper CH2 loops of an aglycosylated Fc variant (Fc5: E382V/M428) and used a high-throughput flow cytometry library screening method, combined with bacterial display of homodimeric Fc domains for enhanced FcγR binding affinity. The trastuzumab Fc variant containing the identified mutations (Q295R, L328W, A330V, P331A, I332Y, E382V, M428I) not only exhibited over 120 fold higher affinity of specific binding to FcγRI than wild type aglycosylated Fc, but also retained pH-dependent FcRn binding. These results show that an aglycosylated antibody expressed in bacteria can be evolved for novel FcγR affinity and specificity.",
keywords = "antibody Fc, directed evolution, effector functions, FcγRI (CD64), neonatal Fc receptor (FcRn)",
author = "Jung, {Sang Taek} and Kang, {Tae Hyun} and Kim, {Dong il}",
year = "2014",
month = "11",
day = "20",
doi = "10.1007/s12257-013-0432-z",
language = "English",
volume = "19",
pages = "780--789",
journal = "Biotechnology and Bioprocess Engineering",
issn = "1226-8372",
publisher = "Korean Society for Biotechnology and Bioengineering",
number = "5",

}

TY - JOUR

T1 - Engineering an aglycosylated Fc variant for enhanced FcγRI engagement and pH-dependent human FcRn binding

AU - Jung, Sang Taek

AU - Kang, Tae Hyun

AU - Kim, Dong il

PY - 2014/11/20

Y1 - 2014/11/20

N2 - The clinical use of therapeutic antibodies has increased sharply because of their many advantages over conventional small molecule drugs, particularly with respect to their affinity, specificity, and serum stability. Tumor or infected cells are removed by the binding of antibody Fc regions to Fc gamma receptors (FcγRs), which stimulate the activation of immune effector cells. Aglycosylated full-length IgG antibodies expressed in bacteria have different Fc conformations compared to their glycosylated counterparts produced in mammalian cells. As a result, they are unable to bind FcγRs, resulting in little to no activation of immune effector cells. In this study, we created a combinatorial library randomized at the upper CH2 loops of an aglycosylated Fc variant (Fc5: E382V/M428) and used a high-throughput flow cytometry library screening method, combined with bacterial display of homodimeric Fc domains for enhanced FcγR binding affinity. The trastuzumab Fc variant containing the identified mutations (Q295R, L328W, A330V, P331A, I332Y, E382V, M428I) not only exhibited over 120 fold higher affinity of specific binding to FcγRI than wild type aglycosylated Fc, but also retained pH-dependent FcRn binding. These results show that an aglycosylated antibody expressed in bacteria can be evolved for novel FcγR affinity and specificity.

AB - The clinical use of therapeutic antibodies has increased sharply because of their many advantages over conventional small molecule drugs, particularly with respect to their affinity, specificity, and serum stability. Tumor or infected cells are removed by the binding of antibody Fc regions to Fc gamma receptors (FcγRs), which stimulate the activation of immune effector cells. Aglycosylated full-length IgG antibodies expressed in bacteria have different Fc conformations compared to their glycosylated counterparts produced in mammalian cells. As a result, they are unable to bind FcγRs, resulting in little to no activation of immune effector cells. In this study, we created a combinatorial library randomized at the upper CH2 loops of an aglycosylated Fc variant (Fc5: E382V/M428) and used a high-throughput flow cytometry library screening method, combined with bacterial display of homodimeric Fc domains for enhanced FcγR binding affinity. The trastuzumab Fc variant containing the identified mutations (Q295R, L328W, A330V, P331A, I332Y, E382V, M428I) not only exhibited over 120 fold higher affinity of specific binding to FcγRI than wild type aglycosylated Fc, but also retained pH-dependent FcRn binding. These results show that an aglycosylated antibody expressed in bacteria can be evolved for novel FcγR affinity and specificity.

KW - antibody Fc

KW - directed evolution

KW - effector functions

KW - FcγRI (CD64)

KW - neonatal Fc receptor (FcRn)

UR - http://www.scopus.com/inward/record.url?scp=84904364868&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84904364868&partnerID=8YFLogxK

U2 - 10.1007/s12257-013-0432-z

DO - 10.1007/s12257-013-0432-z

M3 - Article

AN - SCOPUS:84904364868

VL - 19

SP - 780

EP - 789

JO - Biotechnology and Bioprocess Engineering

JF - Biotechnology and Bioprocess Engineering

SN - 1226-8372

IS - 5

ER -